AU2009314629B2 - Methods and compositions related to targeting monoacylglycerol lipase - Google Patents

Info

Publication number

AU2009314629B2

AU2009314629B2 AU2009314629A AU2009314629A AU2009314629B2 AU 2009314629 B2 AU2009314629 B2 AU 2009314629B2 AU 2009314629 A AU2009314629 A AU 2009314629A AU 2009314629 A AU2009314629 A AU 2009314629A AU 2009314629 B2 AU2009314629 B2 AU 2009314629B2

Authority

AU

Australia

Prior art keywords

magl

cells

compound

cancer

tumor

Prior art date

2008-11-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 108020002334 Monoacylglycerol lipase Proteins 0.000 title claims abstract description 341
• 102000005398 Monoacylglycerol Lipase Human genes 0.000 title claims abstract description 337
• 238000000034 method Methods 0.000 title claims abstract description 116
• 230000008685 targeting Effects 0.000 title abstract description 10
• 239000000203 mixture Substances 0.000 title description 24
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 238
• 201000011510 cancer Diseases 0.000 claims abstract description 177
• 150000001875 compounds Chemical class 0.000 claims abstract description 123
• 230000011664 signaling Effects 0.000 claims abstract description 45
• 150000001200 N-acyl ethanolamides Chemical class 0.000 claims abstract description 39
• 239000002621 endocannabinoid Substances 0.000 claims abstract description 39
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 39
• 230000001404 mediated effect Effects 0.000 claims abstract description 32
• RCRCTBLIHCHWDZ-DOFZRALJSA-N 2-arachidonoylglycerol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-DOFZRALJSA-N 0.000 claims abstract description 7
• 210000004027 cell Anatomy 0.000 claims description 310
• RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 claims description 138
• 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 claims description 75
• 108010046094 fatty-acid amide hydrolase Proteins 0.000 claims description 75
• 102000004157 Hydrolases Human genes 0.000 claims description 63
• 108090000604 Hydrolases Proteins 0.000 claims description 63
• 208000002193 Pain Diseases 0.000 claims description 52
• 230000005764 inhibitory process Effects 0.000 claims description 48
• 230000036407 pain Effects 0.000 claims description 47
• 210000004881 tumor cell Anatomy 0.000 claims description 30
• 241000282414 Homo sapiens Species 0.000 claims description 25
• 230000001225 therapeutic effect Effects 0.000 claims description 23
• 201000001441 melanoma Diseases 0.000 claims description 22
• 239000008194 pharmaceutical composition Substances 0.000 claims description 17
• 101000929834 Homo sapiens Monoacylglycerol lipase ABHD6 Proteins 0.000 claims description 14
• 102100035912 Monoacylglycerol lipase ABHD6 Human genes 0.000 claims description 14
• 230000012010 growth Effects 0.000 claims description 14
• 208000024891 symptom Diseases 0.000 claims description 13
• 206010061218 Inflammation Diseases 0.000 claims description 11
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
• 230000004054 inflammatory process Effects 0.000 claims description 11
• 208000019901 Anxiety disease Diseases 0.000 claims description 10
• 230000036506 anxiety Effects 0.000 claims description 10
• 206010006187 Breast cancer Diseases 0.000 claims description 8
• 208000026310 Breast neoplasm Diseases 0.000 claims description 8
• 230000004936 stimulating effect Effects 0.000 claims description 7
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
• 208000020816 lung neoplasm Diseases 0.000 claims description 6
• 208000037841 lung tumor Diseases 0.000 claims description 5
• 208000030159 metabolic disease Diseases 0.000 claims description 5
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• 208000010412 Glaucoma Diseases 0.000 claims description 3
• 230000002757 inflammatory effect Effects 0.000 claims description 3
• 208000011580 syndromic disease Diseases 0.000 claims description 3
• 239000003112 inhibitor Substances 0.000 abstract description 60
• 229940124639 Selective inhibitor Drugs 0.000 abstract description 53
• 230000004614 tumor growth Effects 0.000 abstract description 34
• 238000001727 in vivo Methods 0.000 abstract description 32
• 238000012216 screening Methods 0.000 abstract description 13
• 230000001976 improved effect Effects 0.000 abstract description 11
• SEGYOKHGGFKMCX-UHFFFAOYSA-N 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]-1-piperidinecarboxylic acid (4-nitrophenyl) ester Chemical compound C=1C=C2OCOC2=CC=1C(C=1C=C2OCOC2=CC=1)(O)C(CC1)CCN1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 SEGYOKHGGFKMCX-UHFFFAOYSA-N 0.000 description 133
• 230000000694 effects Effects 0.000 description 118
• 235000021588 free fatty acids Nutrition 0.000 description 94
• 210000004556 brain Anatomy 0.000 description 81
• 201000009030 Carcinoma Diseases 0.000 description 63
• 238000011282 treatment Methods 0.000 description 58
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 54
• 150000002632 lipids Chemical class 0.000 description 48
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 47
• 241000699670 Mus sp. Species 0.000 description 44
• 108010026552 Proteome Proteins 0.000 description 40
• 208000035475 disorder Diseases 0.000 description 38
• 230000005012 migration Effects 0.000 description 38
• 208000015707 frontal fibrosing alopecia Diseases 0.000 description 37
• 238000013508 migration Methods 0.000 description 37
• 102000004190 Enzymes Human genes 0.000 description 36
• 108090000790 Enzymes Proteins 0.000 description 36
• 229940088598 enzyme Drugs 0.000 description 36
• 238000006243 chemical reaction Methods 0.000 description 35
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
• 239000012528 membrane Substances 0.000 description 33
• 238000004458 analytical method Methods 0.000 description 32
• 229930003827 cannabinoid Natural products 0.000 description 32
• 239000003557 cannabinoid Substances 0.000 description 32
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
• 230000003542 behavioural effect Effects 0.000 description 29
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 28
• 239000005557 antagonist Substances 0.000 description 28
• 150000002759 monoacylglycerols Chemical class 0.000 description 28
• IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 28
• 108090000623 proteins and genes Proteins 0.000 description 25
• 239000003981 vehicle Substances 0.000 description 25
• 238000006460 hydrolysis reaction Methods 0.000 description 23
• 208000032839 leukemia Diseases 0.000 description 23
• 238000003556 assay Methods 0.000 description 22
• 230000007062 hydrolysis Effects 0.000 description 22
• LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 21
• 235000018102 proteins Nutrition 0.000 description 21
• 102000004169 proteins and genes Human genes 0.000 description 21
• 239000000758 substrate Substances 0.000 description 21
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
• 241000699666 Mus <mouse, genus> Species 0.000 description 20
• 206010039491 Sarcoma Diseases 0.000 description 20
• 230000003301 hydrolyzing effect Effects 0.000 description 20
• 230000002829 reductive effect Effects 0.000 description 20
• 239000003795 chemical substances by application Substances 0.000 description 19
• 230000001965 increasing effect Effects 0.000 description 19
• 239000000523 sample Substances 0.000 description 19
• 230000014509 gene expression Effects 0.000 description 18
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 18
• 230000009467 reduction Effects 0.000 description 18
• 239000000126 substance Substances 0.000 description 18
• 238000000338 in vitro Methods 0.000 description 17
• 239000002207 metabolite Substances 0.000 description 17
• 230000007781 signaling event Effects 0.000 description 17
• 230000015572 biosynthetic process Effects 0.000 description 16
• 230000001419 dependent effect Effects 0.000 description 16
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
• 201000010099 disease Diseases 0.000 description 16
• 239000000194 fatty acid Substances 0.000 description 16
• 239000002953 phosphate buffered saline Substances 0.000 description 16
• 108090000765 processed proteins & peptides Proteins 0.000 description 16
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
• 108091027967 Small hairpin RNA Proteins 0.000 description 15
• 238000005259 measurement Methods 0.000 description 15
• 239000000499 gel Substances 0.000 description 14
• 238000007912 intraperitoneal administration Methods 0.000 description 14
• 229960003015 rimonabant Drugs 0.000 description 14
• 239000004055 small Interfering RNA Substances 0.000 description 14
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
• 230000002255 enzymatic effect Effects 0.000 description 13
• 230000009545 invasion Effects 0.000 description 13
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 13
• JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 13
• 230000004083 survival effect Effects 0.000 description 13
• 238000003786 synthesis reaction Methods 0.000 description 13
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 12
• 230000002860 competitive effect Effects 0.000 description 12
• 235000014113 dietary fatty acids Nutrition 0.000 description 12
• 229930195729 fatty acid Natural products 0.000 description 12
• 230000007918 pathogenicity Effects 0.000 description 12
• 108091033319 polynucleotide Proteins 0.000 description 12
• 102000040430 polynucleotide Human genes 0.000 description 12
• 102000004196 processed proteins & peptides Human genes 0.000 description 12
• -1 C16:0 MAGs Chemical class 0.000 description 11
• 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 11
• 241001465754 Metazoa Species 0.000 description 11
• 230000036592 analgesia Effects 0.000 description 11
• 239000002246 antineoplastic agent Substances 0.000 description 11
• 229940114079 arachidonic acid Drugs 0.000 description 11
• 235000021342 arachidonic acid Nutrition 0.000 description 11
• 230000003247 decreasing effect Effects 0.000 description 11
• 239000003814 drug Substances 0.000 description 11
• 150000004665 fatty acids Chemical class 0.000 description 11
• 230000000144 pharmacologic effect Effects 0.000 description 11
• 239000002157 polynucleotide Substances 0.000 description 11
• 239000000047 product Substances 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
• CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 10
• LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 10
• 235000019439 ethyl acetate Nutrition 0.000 description 10
• 230000002503 metabolic effect Effects 0.000 description 10
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 10
• 230000008058 pain sensation Effects 0.000 description 10
• 102000005962 receptors Human genes 0.000 description 10
• 108020003175 receptors Proteins 0.000 description 10
• RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 9
• 108020004635 Complementary DNA Proteins 0.000 description 9
• 230000004071 biological effect Effects 0.000 description 9
• 230000001617 migratory effect Effects 0.000 description 9
• 239000012071 phase Substances 0.000 description 9
• 229920001184 polypeptide Polymers 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• 239000004017 serum-free culture medium Substances 0.000 description 9
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 230000003595 spectral effect Effects 0.000 description 9
• 229940122357 Monoacylglycerol lipase inhibitor Drugs 0.000 description 8
• 239000007983 Tris buffer Substances 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• 238000002474 experimental method Methods 0.000 description 8
• 238000003818 flash chromatography Methods 0.000 description 8
• 235000009200 high fat diet Nutrition 0.000 description 8
• 230000002631 hypothermal effect Effects 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 230000003211 malignant effect Effects 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
• ZIFSFLGSUTZFCP-ZQCNBMBSSA-N n-[5-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]pentyl]-10-[ethoxy(fluoro)phosphoryl]decanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCNC(=O)CCCCCCCCCP(F)(=O)OCC)SC[C@@H]21 ZIFSFLGSUTZFCP-ZQCNBMBSSA-N 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
• 230000000381 tumorigenic effect Effects 0.000 description 8
• 239000013598 vector Substances 0.000 description 8
• 108020004459 Small interfering RNA Proteins 0.000 description 7
• ROFVXGGUISEHAM-UHFFFAOYSA-N URB597 Chemical compound NC(=O)C1=CC=CC(C=2C=C(OC(=O)NC3CCCCC3)C=CC=2)=C1 ROFVXGGUISEHAM-UHFFFAOYSA-N 0.000 description 7
• 230000027455 binding Effects 0.000 description 7
• 238000012737 microarray-based gene expression Methods 0.000 description 7
• 238000012243 multiplex automated genomic engineering Methods 0.000 description 7
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
• 239000012044 organic layer Substances 0.000 description 7
• 230000002018 overexpression Effects 0.000 description 7
• 238000007254 oxidation reaction Methods 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 230000035945 sensitivity Effects 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• 208000000187 Abnormal Reflex Diseases 0.000 description 6
• 102000018208 Cannabinoid Receptor Human genes 0.000 description 6
• 108050007331 Cannabinoid receptor Proteins 0.000 description 6
• 102000038427 NEDD8-activating enzyme E1 Human genes 0.000 description 6
• 108091007790 NEDD8-activating enzyme E1 Proteins 0.000 description 6
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 6
• 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 6
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
• 230000001154 acute effect Effects 0.000 description 6
• 230000009286 beneficial effect Effects 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000009368 gene silencing by RNA Effects 0.000 description 6
• 238000004896 high resolution mass spectrometry Methods 0.000 description 6
• 206010020745 hyperreflexia Diseases 0.000 description 6
• 230000035859 hyperreflexia Effects 0.000 description 6
• 238000007654 immersion Methods 0.000 description 6
• 230000001771 impaired effect Effects 0.000 description 6
• 238000004519 manufacturing process Methods 0.000 description 6
• 230000002611 ovarian Effects 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 210000003491 skin Anatomy 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 231100000588 tumorigenic Toxicity 0.000 description 6
• 208000009132 Catalepsy Diseases 0.000 description 5
• 101001128911 Homo sapiens Neutral cholesterol ester hydrolase 1 Proteins 0.000 description 5
• 102100032087 Neutral cholesterol ester hydrolase 1 Human genes 0.000 description 5
• 206010033128 Ovarian cancer Diseases 0.000 description 5
• 238000011579 SCID mouse model Methods 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 206010047853 Waxy flexibility Diseases 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• 239000000730 antalgic agent Substances 0.000 description 5
• 230000003190 augmentative effect Effects 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 210000004204 blood vessel Anatomy 0.000 description 5
• 238000010804 cDNA synthesis Methods 0.000 description 5
• 229940065144 cannabinoids Drugs 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 238000012512 characterization method Methods 0.000 description 5
• 238000002512 chemotherapy Methods 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• 230000007547 defect Effects 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 239000003940 fatty acid amidase inhibitor Substances 0.000 description 5
• 238000011065 in-situ storage Methods 0.000 description 5
• 150000002500 ions Chemical class 0.000 description 5
• YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 5
• FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 5
• 230000036961 partial effect Effects 0.000 description 5
• 230000001717 pathogenic effect Effects 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 238000002098 selective ion monitoring Methods 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 238000003756 stirring Methods 0.000 description 5
• 238000001262 western blot Methods 0.000 description 5
• NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 4
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
• 206010009944 Colon cancer Diseases 0.000 description 4
• 102000001301 EGF receptor Human genes 0.000 description 4
• 108060006698 EGF receptor Proteins 0.000 description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
• 108700011259 MicroRNAs Proteins 0.000 description 4
• AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 4
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
• 235000021314 Palmitic acid Nutrition 0.000 description 4
• 238000010847 SEQUEST Methods 0.000 description 4
• 208000006011 Stroke Diseases 0.000 description 4
• 230000001594 aberrant effect Effects 0.000 description 4
• 150000001413 amino acids Chemical class 0.000 description 4
• 230000036528 appetite Effects 0.000 description 4
• 235000019789 appetite Nutrition 0.000 description 4
• 239000013592 cell lysate Substances 0.000 description 4
• 230000012292 cell migration Effects 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 230000000052 comparative effect Effects 0.000 description 4
• 230000000875 corresponding effect Effects 0.000 description 4
• 239000010779 crude oil Substances 0.000 description 4
• 229940127089 cytotoxic agent Drugs 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 230000006735 deficit Effects 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• 150000001982 diacylglycerols Chemical class 0.000 description 4
• 235000005911 diet Nutrition 0.000 description 4
• 230000037213 diet Effects 0.000 description 4
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
• 238000001035 drying Methods 0.000 description 4
• 238000000132 electrospray ionisation Methods 0.000 description 4
• 235000019253 formic acid Nutrition 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 238000002825 functional assay Methods 0.000 description 4
• 239000007789 gas Substances 0.000 description 4
• 238000009650 gentamicin protection assay Methods 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 239000007928 intraperitoneal injection Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 238000010232 migration assay Methods 0.000 description 4
• 201000010879 mucinous adenocarcinoma Diseases 0.000 description 4
• 210000000653 nervous system Anatomy 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 150000007523 nucleic acids Chemical class 0.000 description 4
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 4
• 229960001243 orlistat Drugs 0.000 description 4
• 238000011533 pre-incubation Methods 0.000 description 4
• 230000001603 reducing effect Effects 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 238000001228 spectrum Methods 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
• 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 3
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
• 108010024976 Asparaginase Proteins 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 3
• 229940124802 CB1 antagonist Drugs 0.000 description 3
• 208000009458 Carcinoma in Situ Diseases 0.000 description 3
• 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 3
• 208000029147 Collagen-vascular disease Diseases 0.000 description 3
• 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 3
• 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 description 3
• 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 description 3
• 101000742901 Homo sapiens Lysophosphatidylserine lipase ABHD12 Proteins 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 102100038056 Lysophosphatidylserine lipase ABHD12 Human genes 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
• 208000028389 Nerve injury Diseases 0.000 description 3
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
• 108010081690 Pertussis Toxin Proteins 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 235000021355 Stearic acid Nutrition 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 239000000908 ammonium hydroxide Substances 0.000 description 3
• 230000002095 anti-migrative effect Effects 0.000 description 3
• 230000000692 anti-sense effect Effects 0.000 description 3
• 229940034982 antineoplastic agent Drugs 0.000 description 3
• TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• 230000001851 biosynthetic effect Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 210000000481 breast Anatomy 0.000 description 3
• 239000012267 brine Substances 0.000 description 3
• 239000004202 carbamide Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 230000002354 daily effect Effects 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 230000005014 ectopic expression Effects 0.000 description 3
• 238000001952 enzyme assay Methods 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 206010017758 gastric cancer Diseases 0.000 description 3
• 230000002779 inactivation Effects 0.000 description 3
• 230000004968 inflammatory condition Effects 0.000 description 3
• 208000027866 inflammatory disease Diseases 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 150000002611 lead compounds Chemical class 0.000 description 3
• 235000019626 lipase activity Nutrition 0.000 description 3
• 230000002366 lipolytic effect Effects 0.000 description 3
• 239000012160 loading buffer Substances 0.000 description 3
• 208000003747 lymphoid leukemia Diseases 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 208000025113 myeloid leukemia Diseases 0.000 description 3
• 210000005036 nerve Anatomy 0.000 description 3
• 230000008764 nerve damage Effects 0.000 description 3
• 125000003729 nucleotide group Chemical group 0.000 description 3
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 230000003647 oxidation Effects 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 230000009038 pharmacological inhibition Effects 0.000 description 3
• 230000035790 physiological processes and functions Effects 0.000 description 3
• 238000002203 pretreatment Methods 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 208000000649 small cell carcinoma Diseases 0.000 description 3
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
• 238000000527 sonication Methods 0.000 description 3
• 239000008117 stearic acid Substances 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 230000002459 sustained effect Effects 0.000 description 3
• 230000002194 synthesizing effect Effects 0.000 description 3
• 238000004885 tandem mass spectrometry Methods 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 3
• PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
• HSVDYEDYDOKETI-UHFFFAOYSA-N 1,2-dihydroxy-2-(hydroxymethyl)octadecan-3-one Chemical compound CCCCCCCCCCCCCCCC(=O)C(O)(CO)CO HSVDYEDYDOKETI-UHFFFAOYSA-N 0.000 description 2
• XXDBOGXZKIODTO-UHFFFAOYSA-N 1-o-benzyl 4-o-ethyl piperidine-1,4-dicarboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)OCC1=CC=CC=C1 XXDBOGXZKIODTO-UHFFFAOYSA-N 0.000 description 2
• 238000004780 2D liquid chromatography Methods 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
• 208000007848 Alcoholism Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 2
• 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 2
• 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 2
• 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 208000001387 Causalgia Diseases 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 206010008583 Chloroma Diseases 0.000 description 2
• 208000006332 Choriocarcinoma Diseases 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
• 208000015872 Gaucher disease Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101001012646 Homo sapiens Monoglyceride lipase Proteins 0.000 description 2
• 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 2
• 208000004454 Hyperalgesia Diseases 0.000 description 2
• 208000035154 Hyperesthesia Diseases 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 206010053574 Immunoblastic lymphoma Diseases 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 239000005642 Oleic acid Substances 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 201000001542 Schneiderian carcinoma Diseases 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• 208000022292 Tay-Sachs disease Diseases 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
• 241000482268 Zea mays subsp. mays Species 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 206010000269 abscess Diseases 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 208000036676 acute undifferentiated leukemia Diseases 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 208000002517 adenoid cystic carcinoma Diseases 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 238000002266 amputation Methods 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 229940035676 analgesics Drugs 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 229940114078 arachidonate Drugs 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 230000002903 catalepsic effect Effects 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 230000000973 chemotherapeutic effect Effects 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 229960002986 dinoprostone Drugs 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 229940121647 egfr inhibitor Drugs 0.000 description 2
• 230000003028 elevating effect Effects 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 230000007071 enzymatic hydrolysis Effects 0.000 description 2
• 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 235000019197 fats Nutrition 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 150000004676 glycans Chemical class 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 201000004933 in situ carcinoma Diseases 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 230000006742 locomotor activity Effects 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000025036 lymphosarcoma Diseases 0.000 description 2
• 108010082117 matrigel Proteins 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000015654 memory Effects 0.000 description 2
• 238000001466 metabolic labeling Methods 0.000 description 2
• 239000002679 microRNA Substances 0.000 description 2
• 239000003607 modifier Substances 0.000 description 2
• 201000006894 monocytic leukemia Diseases 0.000 description 2
• 201000005518 mononeuropathy Diseases 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 201000005987 myeloid sarcoma Diseases 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 208000004296 neuralgia Diseases 0.000 description 2
• 208000021722 neuropathic pain Diseases 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 239000002858 neurotransmitter agent Substances 0.000 description 2
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
• BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
• 230000001473 noxious effect Effects 0.000 description 2
• 238000010899 nucleation Methods 0.000 description 2
• 239000012038 nucleophile Substances 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
• HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 description 2
• 231100000255 pathogenic effect Toxicity 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
• RJUAEBLXGFKZMS-UHFFFAOYSA-N piperidin-1-ylmethanol Chemical group OCN1CCCCC1 RJUAEBLXGFKZMS-UHFFFAOYSA-N 0.000 description 2
• 208000031223 plasma cell leukemia Diseases 0.000 description 2
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
• 150000003180 prostaglandins Chemical class 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 229940076788 pyruvate Drugs 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
• 238000007790 scraping Methods 0.000 description 2
• 230000020341 sensory perception of pain Effects 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 201000011549 stomach cancer Diseases 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000036962 time dependent Effects 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 150000003626 triacylglycerols Chemical class 0.000 description 2
• 206010044652 trigeminal neuralgia Diseases 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• CJDRUOGAGYHKKD-XMTJACRCSA-N (+)-Ajmaline Natural products O[C@H]1[C@@H](CC)[C@@H]2[C@@H]3[C@H](O)[C@@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@H]3C5)C2 CJDRUOGAGYHKKD-XMTJACRCSA-N 0.000 description 1
• DZLOHEOHWICNIL-QGZVFWFLSA-N (2R)-2-[6-(4-chlorophenoxy)hexyl]-2-oxiranecarboxylic acid ethyl ester Chemical compound C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)OCC)CO1 DZLOHEOHWICNIL-QGZVFWFLSA-N 0.000 description 1
• XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
• SWFHGTMLYIBPPA-UHFFFAOYSA-N (4-methoxyphenyl)-phenylmethanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 SWFHGTMLYIBPPA-UHFFFAOYSA-N 0.000 description 1
• SCGWVDIBSUKCMG-UHFFFAOYSA-N (4-nitrophenyl) piperazine-1-carboxylate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)N1CCNCC1 SCGWVDIBSUKCMG-UHFFFAOYSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• GBXRUYNQDDTQQS-UHFFFAOYSA-N 1-O-dodecylglycerol Chemical compound CCCCCCCCCCCCOCC(O)CO GBXRUYNQDDTQQS-UHFFFAOYSA-N 0.000 description 1
• TTXIFFYPVGWLSE-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCNCC1 TTXIFFYPVGWLSE-UHFFFAOYSA-N 0.000 description 1
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
• KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• 229940119225 3-Ketoacyl coenzyme A thiolase inhibitor Drugs 0.000 description 1
• WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
• RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
• FBOYMIDCHINJKC-UHFFFAOYSA-N 5-bromo-1,3-benzodioxole Chemical compound BrC1=CC=C2OCOC2=C1 FBOYMIDCHINJKC-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
• 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
• 101710175445 Acyl-coenzyme A thioesterase 1 Proteins 0.000 description 1
• 102100025854 Acyl-coenzyme A thioesterase 1 Human genes 0.000 description 1
• 102100025851 Acyl-coenzyme A thioesterase 2, mitochondrial Human genes 0.000 description 1
• 102100040277 Acyl-protein thioesterase 2 Human genes 0.000 description 1
• 102100032488 Acylamino-acid-releasing enzyme Human genes 0.000 description 1
• 241000321096 Adenoides Species 0.000 description 1
• 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• 206010049589 Afterbirth pain Diseases 0.000 description 1
• 208000035805 Aleukaemic leukaemia Diseases 0.000 description 1
• 102100038046 Alpha/beta hydrolase domain-containing protein 17A Human genes 0.000 description 1
• 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 200000000007 Arterial disease Diseases 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 208000025978 Athletic injury Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 208000013165 Bowen disease Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
• 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
• 102100037885 Calcium-independent phospholipase A2-gamma Human genes 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 244000025254 Cannabis sativa Species 0.000 description 1
• 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
• 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
• 108010051152 Carboxylesterase Proteins 0.000 description 1
• 102000013392 Carboxylesterase Human genes 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 206010062746 Carditis Diseases 0.000 description 1
• 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
• 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010059081 Cathepsin A Proteins 0.000 description 1
• 102000005572 Cathepsin A Human genes 0.000 description 1
• 206010064012 Central pain syndrome Diseases 0.000 description 1
• 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 208000034656 Contusions Diseases 0.000 description 1
• 101150073133 Cpt1a gene Proteins 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 238000000018 DNA microarray Methods 0.000 description 1
• 208000020401 Depressive disease Diseases 0.000 description 1
• 206010012434 Dermatitis allergic Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 101100054330 Dictyostelium discoideum abhd gene Proteins 0.000 description 1
• 102100036968 Dipeptidyl peptidase 8 Human genes 0.000 description 1
• 102100036969 Dipeptidyl peptidase 9 Human genes 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 206010057649 Endometrial sarcoma Diseases 0.000 description 1
• 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 240000001624 Espostoa lanata Species 0.000 description 1
• 235000009161 Espostoa lanata Nutrition 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• 102000047352 Esterase-like Human genes 0.000 description 1
• 108700037229 Esterase-like Proteins 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 208000035874 Excoriation Diseases 0.000 description 1
• 208000001382 Experimental Melanoma Diseases 0.000 description 1
• 208000009331 Experimental Sarcoma Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 208000027472 Galactosemias Diseases 0.000 description 1
• 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 206010019973 Herpes virus infection Diseases 0.000 description 1
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000017662 Hodgkin disease lymphocyte depletion type stage unspecified Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 101000720371 Homo sapiens Acyl-coenzyme A thioesterase 2, mitochondrial Proteins 0.000 description 1
• 101000742837 Homo sapiens Alpha/beta hydrolase domain-containing protein 17A Proteins 0.000 description 1
• 101001095970 Homo sapiens Calcium-independent phospholipase A2-gamma Proteins 0.000 description 1
• 101000804947 Homo sapiens Dipeptidyl peptidase 8 Proteins 0.000 description 1
• 101000804945 Homo sapiens Dipeptidyl peptidase 9 Proteins 0.000 description 1
• 101000956612 Homo sapiens Lysophospholipase-like protein 1 Proteins 0.000 description 1
• 101000677825 Homo sapiens Palmitoyl-protein thioesterase ABHD10, mitochondrial Proteins 0.000 description 1
• 101000760646 Homo sapiens Phosphatidylserine lipase ABHD16A Proteins 0.000 description 1
• 101000613133 Homo sapiens Phospholipase A2 group XV Proteins 0.000 description 1
• 101000929845 Homo sapiens Phospholipase ABHD3 Proteins 0.000 description 1
• 101001097889 Homo sapiens Platelet-activating factor acetylhydrolase Proteins 0.000 description 1
• 101001095240 Homo sapiens Prolyl endopeptidase-like Proteins 0.000 description 1
• 101000677831 Homo sapiens Protein ABHD11 Proteins 0.000 description 1
• 101001095294 Homo sapiens Protein phosphatase methylesterase 1 Proteins 0.000 description 1
• 101001112429 Homo sapiens Serine hydrolase RBBP9 Proteins 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 210000005131 Hürthle cell Anatomy 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 206010023256 Juvenile melanoma benign Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 241000283891 Kobus Species 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• 206010024218 Lentigo maligna Diseases 0.000 description 1
• 206010053180 Leukaemia cutis Diseases 0.000 description 1
• 206010024305 Leukaemia monocytic Diseases 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 1
• 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 description 1
• 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 description 1
• 102100037611 Lysophospholipase Human genes 0.000 description 1
• 102100038490 Lysophospholipase-like protein 1 Human genes 0.000 description 1
• 102100033320 Lysosomal Pro-X carboxypeptidase Human genes 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000030162 Maple syrup disease Diseases 0.000 description 1
• 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 description 1
• 208000007054 Medullary Carcinoma Diseases 0.000 description 1
• 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010059521 Methylmalonic aciduria Diseases 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
• 206010027918 Mononeuropathy multiplex Diseases 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 1
• 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
• 206010029240 Neuritis Diseases 0.000 description 1
• 208000001294 Nociceptive Pain Diseases 0.000 description 1
• 206010029488 Nodular melanoma Diseases 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108010058846 Ovalbumin Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 102100021498 Palmitoyl-protein thioesterase ABHD10, mitochondrial Human genes 0.000 description 1
• 102100031254 Patatin-like phospholipase domain-containing protein 6 Human genes 0.000 description 1
• 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
• 208000020547 Peroxisomal disease Diseases 0.000 description 1
• 201000011252 Phenylketonuria Diseases 0.000 description 1
• 102100024634 Phosphatidylserine lipase ABHD16A Human genes 0.000 description 1
• 102100040865 Phospholipase A2 group XV Human genes 0.000 description 1
• 102100035907 Phospholipase ABHD3 Human genes 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 108010058864 Phospholipases A2 Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 102100037518 Platelet-activating factor acetylhydrolase Human genes 0.000 description 1
• 229920005372 Plexiglas® Polymers 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 241000097929 Porphyria Species 0.000 description 1
• 208000010642 Porphyrias Diseases 0.000 description 1
• 208000004550 Postoperative Pain Diseases 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 102100037822 Prolyl endopeptidase-like Human genes 0.000 description 1
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
• 102100038950 Proprotein convertase subtilisin/kexin type 7 Human genes 0.000 description 1
• 102100021499 Protein ABHD11 Human genes 0.000 description 1
• 102100037834 Protein phosphatase methylesterase 1 Human genes 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 206010038997 Retroviral infections Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 101000596942 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Triacylglycerol lipase 2 Proteins 0.000 description 1
• 102100023569 Serine hydrolase RBBP9 Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 208000010040 Sprains and Strains Diseases 0.000 description 1
• 206010042496 Sunburn Diseases 0.000 description 1
• 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 208000002903 Thalassemia Diseases 0.000 description 1
• 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 241000159243 Toxicodendron radicans Species 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
• 102100040411 Tripeptidyl-peptidase 2 Human genes 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000010399 Wasting Syndrome Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 208000012018 Yolk sac tumor Diseases 0.000 description 1
• 201000004525 Zellweger Syndrome Diseases 0.000 description 1
• 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
• QTWNORFUQILKJL-UHFFFAOYSA-N [4-(4-carbamoylphenyl)phenyl] n-methyl-n-[(3-pyridin-4-ylphenyl)methyl]carbamate Chemical compound C=1C=C(C=2C=CC(=CC=2)C(N)=O)C=CC=1OC(=O)N(C)CC(C=1)=CC=CC=1C1=CC=NC=C1 QTWNORFUQILKJL-UHFFFAOYSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 238000005299 abrasion Methods 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 208000006336 acinar cell carcinoma Diseases 0.000 description 1
• 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 210000002534 adenoid Anatomy 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 206010001689 alkaptonuria Diseases 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 150000001371 alpha-amino acids Chemical class 0.000 description 1
• 235000008206 alpha-amino acids Nutrition 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
• 208000006431 amelanotic melanoma Diseases 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 230000002707 ameloblastic effect Effects 0.000 description 1
• 230000037354 amino acid metabolism Effects 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 230000002917 arthritic effect Effects 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 208000016894 basaloid carcinoma Diseases 0.000 description 1
• 201000000450 basaloid squamous cell carcinoma Diseases 0.000 description 1
• 208000003373 basosquamous carcinoma Diseases 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 230000002051 biphasic effect Effects 0.000 description 1
• 210000003969 blast cell Anatomy 0.000 description 1
• 229960004395 bleomycin sulfate Drugs 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
• 201000010983 breast ductal carcinoma Diseases 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 230000021235 carbamoylation Effects 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 229940106189 ceramide Drugs 0.000 description 1
• 150000001783 ceramides Chemical class 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000013507 chronic prostatitis Diseases 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000011278 co-treatment Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 201000011050 comedo carcinoma Diseases 0.000 description 1
• 238000010835 comparative analysis Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 238000010205 computational analysis Methods 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 201000011063 cribriform carcinoma Diseases 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 238000000315 cryotherapy Methods 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 229960000978 cyproterone acetate Drugs 0.000 description 1
• UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
• 208000002925 dental caries Diseases 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 230000002074 deregulated effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000012912 drug discovery process Methods 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 208000001991 endodermal sinus tumor Diseases 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
• 229960004750 estramustine phosphate Drugs 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 229950006213 etomoxir Drugs 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 230000004129 fatty acid metabolism Effects 0.000 description 1
• 230000004136 fatty acid synthesis Effects 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 230000003328 fibroblastic effect Effects 0.000 description 1
• 206010016629 fibroma Diseases 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 229960005304 fludarabine phosphate Drugs 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 239000000446 fuel Substances 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 208000010749 gastric carcinoma Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 230000034659 glycolysis Effects 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 208000017750 granulocytic sarcoma Diseases 0.000 description 1
• 210000002503 granulosa cell Anatomy 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 230000003118 histopathologic effect Effects 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• 210000004276 hyalin Anatomy 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 230000001422 hypoalgesic effect Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 208000021646 inflammation of heart layer Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
• 238000005040 ion trap Methods 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 230000009191 jumping Effects 0.000 description 1
• 229960004125 ketoconazole Drugs 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 210000001865 kupffer cell Anatomy 0.000 description 1
• 208000003849 large cell carcinoma Diseases 0.000 description 1
• 230000013016 learning Effects 0.000 description 1
• 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 230000000610 leukopenic effect Effects 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 230000013190 lipid storage Effects 0.000 description 1
• 230000004130 lipolysis Effects 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000004943 liquid phase epitaxy Methods 0.000 description 1
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 229960005015 local anesthetics Drugs 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
• 201000000966 lung oat cell carcinoma Diseases 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 108010057284 lysosomal Pro-X carboxypeptidase Proteins 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 206010061526 malignant mesenchymoma Diseases 0.000 description 1
• 208000024393 maple syrup urine disease Diseases 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 208000000516 mast-cell leukemia Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 230000000684 melanotic effect Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 238000006241 metabolic reaction Methods 0.000 description 1
• 230000001431 metabolomic effect Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
• 201000003694 methylmalonic acidemia Diseases 0.000 description 1
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 208000012268 mitochondrial disease Diseases 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 229960003938 moxonidine Drugs 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
• 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 208000020469 nerve plexus disease Diseases 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 230000003040 nociceptive effect Effects 0.000 description 1
• 210000000929 nociceptor Anatomy 0.000 description 1
• 108091008700 nociceptors Proteins 0.000 description 1
• 201000000032 nodular malignant melanoma Diseases 0.000 description 1
• 208000029809 non-keratinizing sinonasal squamous cell carcinoma Diseases 0.000 description 1
• 239000012740 non-selective inhibitor Substances 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 229920002113 octoxynol Polymers 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 230000005959 oncogenic signaling Effects 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 238000006053 organic reaction Methods 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 229940092253 ovalbumin Drugs 0.000 description 1
• 229940124583 pain medication Drugs 0.000 description 1
• 230000037324 pain perception Effects 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 201000005163 papillary serous adenocarcinoma Diseases 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 201000006380 plexopathy Diseases 0.000 description 1
• 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 201000007094 prostatitis Diseases 0.000 description 1
• 238000002731 protein assay Methods 0.000 description 1
• 238000000575 proteomic method Methods 0.000 description 1
• 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 description 1
• 239000008213 purified water Substances 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 238000007674 radiofrequency ablation Methods 0.000 description 1
• 238000009790 rate-determining step (RDS) Methods 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 239000013557 residual solvent Substances 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 208000004124 rheumatic heart disease Diseases 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
• 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
• 208000004259 scirrhous adenocarcinoma Diseases 0.000 description 1
• 238000002805 secondary assay Methods 0.000 description 1
• 229930000044 secondary metabolite Natural products 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 208000005893 serous cystadenoma Diseases 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 231100000274 skin absorption Toxicity 0.000 description 1
• 230000037384 skin absorption Effects 0.000 description 1
• 206010040882 skin lesion Diseases 0.000 description 1
• 231100000444 skin lesion Toxicity 0.000 description 1
• 231100000245 skin permeability Toxicity 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• BMVUIWJCUQSHLZ-YFZGBAIXSA-N sn-Glycero-3-phosphoinositol Chemical compound OC[C@@H](O)COP(O)(=O)OC1[C@H](O)[C@@H](O)C(O)[C@@H](O)[C@H]1O BMVUIWJCUQSHLZ-YFZGBAIXSA-N 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 238000002798 spectrophotometry method Methods 0.000 description 1
• 208000011584 spitz nevus Diseases 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000037351 starvation Effects 0.000 description 1
• 230000003068 static effect Effects 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• 208000028210 stromal sarcoma Diseases 0.000 description 1
• 238000012799 strong cation exchange Methods 0.000 description 1
• CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
• 229940006509 strontium-89 Drugs 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 201000010033 subleukemic leukemia Diseases 0.000 description 1
• 208000030457 superficial spreading melanoma Diseases 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 229960005314 suramin Drugs 0.000 description 1
• FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000003956 synaptic plasticity Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 208000037905 systemic hypertension Diseases 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 238000000015 thermotherapy Methods 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 229960001177 trimetazidine Drugs 0.000 description 1
• 108010039189 tripeptidyl-peptidase 2 Proteins 0.000 description 1
• DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
• GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 238000003828 vacuum filtration Methods 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 208000008662 verrucous carcinoma Diseases 0.000 description 1
• KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
• 229960004982 vinblastine sulfate Drugs 0.000 description 1
• 208000009935 visceral pain Diseases 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 238000003260 vortexing Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 239000002023 wood Substances 0.000 description 1